| Not Yet Recruiting | A Study to Investigate the Long-term Safety, Tolerability and Efficacy of Balinatunfib in Participants With Cr NCT07222189 | Sanofi | Phase 2 |
| Not Yet Recruiting | A Study to Assess Real-world Outcomes for Long-Term Use of Guselkumab NCT07532213 | Janssen-Cilag A.G., Switzerland | — |
| Not Yet Recruiting | A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease NCT07483073 | Eli Lilly and Company | Phase 2 |
| Not Yet Recruiting | A Study of How the Medicine Called "Etrasimod" Works in Children With the Gut Disease Called Ulcerative Coliti NCT07470879 | Pfizer | Phase 2 |
| Not Yet Recruiting | A Study to Evaluate Efficacy and Safety of MK-8690 in Participants With Moderately to Severely Active Ulcerati NCT07463183 | Merck Sharp & Dohme LLC | Phase 2 |
| Enrolling By Invitation | Effectiveness of Health Education as a Nursing Intervention in Improving Quality of Life and Reducing Symptoms NCT07347158 | Hospital Clinico Universitario de Santiago | N/A |
| Not Yet Recruiting | Confirmatory Clinical Study in Active Ulcerative Colitis NCT07296315 | MRM Health NV | Phase 2 |
| Recruiting | A Real-World Study of Guselkumab in Chinese Participants With Ulcerative Colitis NCT07302360 | Xian-Janssen Pharmaceutical Ltd. | — |
| Not Yet Recruiting | OPTImization of Inflammatory Bowel Disease Treatment Through Understanding of Gut VIRome Heterogeneity NCT07240181 | Andreas Munk Petersen | — |
| Recruiting | A Study to Observe Real-world Evidence of Guselkumab Treatment in Participants With Ulcerative Colitis and Cro NCT07242248 | Janssen-Cilag Ltd. | — |
| Recruiting | Magnesium in Gastrointestinal Disease NCT07338565 | University of Aarhus | — |
| Recruiting | A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulce NCT07196748 | Janssen Research & Development, LLC | Phase 3 |
| Recruiting | A Study to Generate Real-world Evidence of Guselkumab Effectiveness in Inflammatory Bowel Disease in Germany NCT07102368 | Janssen-Cilag G.m.b.H | — |
| Recruiting | Acceptability, Adherence, and Impact on the Bioavailability of Iron and Zinc of the Dietary Supplements Goodph NCT07380022 | University of Thessaly | N/A |
| Recruiting | A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis NCT07012395 | Spyre Therapeutics, Inc. | Phase 2 |
| Recruiting | Comparison of Medical RESCUE Strategies for Patients With Steroid-refractory Acute Severe Ulcerative Colitis NCT06660693 | McMaster University | Phase 3 |
| Not Yet Recruiting | LMT503 First-in-human SAD, MAD, and FE Study NCT05659953 | Lmito Therapeutics Inc. | Phase 1 |
| Recruiting | A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Ulcerative Colitis NCT06867094 | Sanofi | Phase 2 |
| Not Yet Recruiting | Remote Monitoring of Patients With an Inflammatory Bowel Disease Under no or Maintenance Therapy NCT06338930 | Universitaire Ziekenhuizen KU Leuven | N/A |
| Recruiting | Investigation of the Correlation Between Polyamine Levels and Their Key Enzymatic Activities in Association Wi NCT06995170 | Xijing Hospital | — |
| Recruiting | Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcer NCT06651281 | Merck Sharp & Dohme LLC | Phase 3 |
| Active Not Recruiting | A First-time in Human (FTIH) Study to Evaluate Safety, Tolerability, Pharmacokinetics and Target Engagement of NCT06681181 | GlaxoSmithKline | Phase 1 |
| Recruiting | A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants NCT06663332 | Janssen Research & Development, LLC | Phase 3 |
| Recruiting | An Observational Study of Etrasimod in Adult Patients With Moderate to Severe Ulcerative Colitis NCT06398626 | Pfizer | — |
| Completed | Single Dose Study of Tulisokibart (MK-7240) in Healthy Chinese Participants (MK-7240-002) NCT06829225 | Merck Sharp & Dohme LLC | Phase 1 |
| Recruiting | A Study to Learn About the Effectiveness of Etrasimod in People With Ulcerative Colitis NCT06294925 | Pfizer | — |
| Recruiting | Texture and Color Enhancement Imaging (TXI) for Inflammation Assessment in Patients With Inflammatory Bowel Di NCT06892990 | University of Ulm | N/A |
| Recruiting | Clinical Characteristics of Sleep Disorders in Patients With Ulcerative Colitis NCT06359808 | Xijing Hospital | — |
| Unknown | Phase III Multicentre Trial of Oral Mesalazine in Patients With Mild to Moderate Ulcerative Colitis. NCT06176560 | Faes Farma, S.A. | Phase 3 |
| Recruiting | A Study of Jyseleca Tablet (Filgotinib Maleate) in Korean Participants NCT06246123 | Eisai Korea Inc. | — |
| Active Not Recruiting | Chronic Care Model on Symptom Status, Stress and Quality of Life in Individuals With Inflammatory Bowel Diseas NCT06757231 | Hasan Kalyoncu University | N/A |
| Active Not Recruiting | A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis NCT06260163 | Janssen Research & Development, LLC | Phase 3 |
| Completed | A Study to Learn About the Study Medicine Called Infliximab (Genetical Recombination)[Infliximab Biosimilar 3] NCT05796245 | Pfizer | — |
| Recruiting | Therapeutic Endpoint in Pediatric IBD Conditions NCT06065228 | Children's National Research Institute | — |
| Withdrawn | A First Time in Human Study to Evaluate the Safety and Tolerability of GSK4381406 in Healthy Participants NCT05999708 | GlaxoSmithKline | Phase 1 |
| Completed | A Study of JNJ-77242113 in Participants With Moderately to Severely Active Ulcerative Colitis NCT06049017 | Janssen Research & Development, LLC | Phase 2 |
| Terminated | VE202 in Patients With Mild-to-Moderate Ulcerative Colitis NCT05370885 | Vedanta Biosciences, Inc. | Phase 2 |
| Completed | An Early Phase 2 Clinical Study of KSP-0243 NCT05831670 | Kissei Pharmaceutical Co., Ltd. | Phase 2 |
| Active Not Recruiting | A Study to Investigate the Efficacy and Safety of Dupilumab Therapy Compared With Placebo in Participants Aged NCT05731128 | Sanofi | Phase 2 |
| Active Not Recruiting | A Study to Evaluate the Long-Term Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Dise NCT05668013 | Teva Branded Pharmaceutical Products R&D LLC | Phase 2 |
| Recruiting | JAK Inhibition in Ulcerative Colitis NCT05456412 | Leiden University Medical Center | N/A |
| Terminated | An Open-label Study of Ozanimod in Moderate to Severe Ulcerative Colitis in Clinical Practice NCT05369832 | Bristol-Myers Squibb | Phase 4 |
| Unknown | Physical Fitness Levels in Children and Adolescents With Chronic Inflammatory Bowel Disease (CIBD): Crohn's Di NCT04647578 | University Hospital, Lille | — |
| Active Not Recruiting | Dose-finding Study of SAR443122 in Adult Participants With Ulcerative Colitis NCT05588843 | Sanofi | Phase 2 |
| Active Not Recruiting | A Study to Evaluate MORF-057 in Adults With Moderately to Severely Active UC NCT05611671 | Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) | Phase 2 |
| Completed | A Study to Test the Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease NCT05499130 | Teva Branded Pharmaceutical Products R&D, Inc. | Phase 2 |
| Active Not Recruiting | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Activ NCT05242484 | Janssen Research & Development, LLC | Phase 2 |
| Active Not Recruiting | A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis NCT05528510 | Janssen Research & Development, LLC | Phase 3 |
| Withdrawn | Therapeutic Modulation of the Intestinal Creatine Kinase System in Inflammatory Bowel Disease (IBD) NCT02463305 | University of Colorado, Denver | EARLY_Phase 1 |
| Terminated | A Study to Evaluate the Utilization, Effectiveness, and Quality of Life of Ozanimod in Participants With Ulcer NCT05382715 | Bristol-Myers Squibb | — |
| Recruiting | A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerat NCT05076175 | Bristol-Myers Squibb | Phase 2 / Phase 3 |
| Completed | Real World Data on Vedolizumab Concentration and Outcomes in Inflammatory Bowel Disease (IBD) Patients Switchi NCT05504915 | Osijek University Hospital | — |
| Completed | A Phase 2a Open-Label Study to Evaluate the Efficacy and Safety of MORF-057 in Adults With UC NCT05291689 | Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) | Phase 2 |
| Completed | A Study on Administration Choices of Vedolizumab and Outcomes for Adults With Inflammatory Bowel Disease (IBD) NCT04885920 | Takeda | — |
| Unknown | Protein and Magnesium in Ulcerative Colitis NCT05271838 | University of Aarhus | N/A |
| Completed | A Study on How Vedolizumab is Given and the Outcomes for Adults With Inflammatory Bowel Disease (VARIETY-Belgi NCT04959851 | Takeda | — |
| Active Not Recruiting | VTX002 Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis NCT05156125 | Oppilan Pharma Ltd | Phase 2 |
| Completed | A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics (PD) of GSK3888130B in Healthy NCT05131971 | GlaxoSmithKline | Phase 1 |
| Completed | A Study of Vedolizumab in Adults in Real-World Practice NCT04872491 | Takeda | — |
| Completed | A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Ulcerative Colitis (UC) NCT04779307 | Takeda | Phase 3 |
| Active Not Recruiting | A Long-term Extension Study of Ustekinumab in Pediatric Participants NCT05092269 | Janssen Research & Development, LLC | Phase 3 |
| Completed | A Study in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) Receiving Vedolizumab in Real-World Pra NCT04989907 | Takeda | — |
| Completed | A Study of Moderate to Severe Inflammatory Bowel Disease, Including Ulcerative Colitis (UC) and Crohn's Diseas NCT04873700 | Takeda | — |
| Completed | A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in Real-World Practice NCT04890262 | Takeda | — |
| Recruiting | A Study to Assess the Long-Term Safety of Ustekinumab Versus Other Biologics in Patients With Crohn's Disease NCT04372108 | Janssen Scientific Affairs, LLC | — |
| Terminated | A Study of LY3471851 in Adult Participants With Moderately to Severely Active Ulcerative Colitis (UC) NCT04677179 | Nektar Therapeutics | Phase 2 |
| Completed | A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis (UC) NCT04630028 | Janssen Research & Development, LLC | Phase 3 |
| Completed | A Study of the Safety, Efficacy, and Biomarker Response of BMS-986165 in Participants With Moderate to Severe NCT04613518 | Bristol-Myers Squibb | Phase 2 |
| Enrolling By Invitation | De-escalation of Anti-TNF Therapy in Inflammatory Bowel Disease NCT04646187 | University Medical Center Groningen | Phase 4 |
| Recruiting | Diet Intervention Treatment for Active Ulcerative Colitis NCT04121806 | Mount Sinai Hospital, Canada | N/A |
| Recruiting | Pharmacologic Weight Loss as Adjunct Therapy for Ulcerative Colitis in Obese Patients NCT04721873 | University of California, San Diego | Phase 2 |
| Completed | Using Vedolizumab-800CW to Gain Insight Into Local Drug Distribution and Mucosal Target Cells in IBD Patients NCT04112212 | University Medical Center Groningen | Phase 1 |
| Completed | Paricipant Preferences in the Treatment of Inflammatory Bowel Disease (IBD) in Europe NCT04597905 | Takeda | — |
| Completed | Study of Relationship Between Vedolizumab Therapeutic Drug Monitoring, Biomarkers of Inflammation and Clinical NCT04567628 | Takeda | — |
| Terminated | A Study of JNJ-66525433 in Healthy Participants and Participants With Ulcerative Colitis NCT04457960 | Janssen Research & Development, LLC | Phase 1 |
| Completed | A Study of Kynteles Injection (Vedolizumab) in Adults With Moderate to Severe Ulcerative Colitis or Crohn's Di NCT04799496 | Takeda | — |
| Active Not Recruiting | Determination of the Optimal Treatment Target in Ulcerative Colitis NCT04259138 | Alimentiv Inc. | Phase 4 |
| Terminated | Study of Efficacy, Safety, and Tolerability of LYS006, in Patients With Mild to Moderate Ulcerative Colitis NCT04074590 | Novartis Pharmaceuticals | Phase 2 |
| Completed | The Associations of Microribonucleic Acid Gene Polymorphisms With the Risk of Ulcerative Colitis NCT06873711 | Second Affiliated Hospital of Wenzhou Medical University | — |
| Terminated | TITRATE (inducTIon for acuTe ulceRATivE Colitis) NCT03937609 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | Phase 4 |
| Terminated | Tofacitinib Registry of Patients With Ulcerative Colitis in Germany NCT04032756 | Ced Service GmbH | — |
| Completed | To Evaluate Efficacy and Long-term Safety of Ozanimod in Japanese Subjects With Moderately to Severely Active NCT03915769 | Celgene | Phase 3 |
| Terminated | Safety, Tolerability, Efficacy and Dose-response of GSK2831781 in Ulcerative Colitis NCT03893565 | GlaxoSmithKline | Phase 2 |
| Active Not Recruiting | Acupuncture in Pediatrics and Adolescents With Chronic Inflammatory Bowel Diseases NCT04488198 | Medical University of Vienna | N/A |
| Completed | A Study to Observe Vedolizumab and Anti-tumour Necrosis Factors (Anti-TNFs) Outcomes in Real-world Biologic Ul NCT03710486 | Takeda | — |
| Terminated | A Study Evaluating the Efficacy and Safety of ST-0529 in Subjects With Moderately to Severely Active Ulcerativ NCT03844932 | Sublimity Therapeutics Holdco Limited | Phase 2 |
| Completed | An Analysis of the Relationship Between the Genetic Polymorphisms of Plasminogen Activator Inhibitor-1 and Ulc NCT06961435 | Second Affiliated Hospital of Wenzhou Medical University | — |
| Completed | A Study to Evaluate Disease Control, Treatment Patterns, Burden of Disease and Quality of Life in Participants NCT03488030 | Takeda | — |
| Completed | A Study of Efficacy and Safety of Combination Therapy With Guselkumab and Golimumab in Participants With Moder NCT03662542 | Janssen Research & Development, LLC | Phase 2 |
| Completed | BI 655130 Long-term Treatment in Patients With moderate-to Severe Ulcerative Colitis NCT03648541 | Boehringer Ingelheim | Phase 2 |
| Active Not Recruiting | A Study to Assess the Efficacy and Safety of Golimumab in Pediatric Participants With Moderately to Severely A NCT03596645 | Janssen Research & Development, LLC | Phase 3 |
| Unknown | Optimization of Golimumab Treatment in Ulcerative Colitis NCT03669029 | Hospital de Manises | Phase 4 |
| Unknown | Prevention of Readmissions at IBD Centres of Excellence NCT02931799 | Mount Sinai Hospital, Canada | N/A |
| Completed | Real-world Effectiveness of Ustekinumab in Participants Suffering From Inflammatory Bowel Disease (Crohn's Dis NCT03606499 | Janssen Cilag S.A.S. | — |
| Completed | COlonic Salvage by Therapeutic Appendectomy. NCT03912714 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | N/A |
| Completed | A Study to Evaluate Disease Control and Treatment Pattern in Participants With Moderate to Severe Inflammatory NCT03532932 | Takeda | — |
| Completed | One-year Persistence to Treatment of Participants Receiving Flixabi or Imraldi: a French Cohort Study NCT03662919 | Biogen | — |
| Completed | A Study to Evaluate the Safety and Efficacy of AJM300 in Participants With Active Ulcerative Colitis NCT03531892 | EA Pharma Co., Ltd. | Phase 3 |
| Unknown | Digital Holographic Microscopy: Evaluation of Histological Disease Activity in Patients With Ulcerative Coliti NCT03464474 | University Hospital Muenster | N/A |
| Completed | BI655130 (SPESOLIMAB) Induction Treatment in Patients With Moderate-to-severe Ulcerative Colitis NCT03482635 | Boehringer Ingelheim | Phase 2 / Phase 3 |
| Terminated | Combined Nutritional Therapies for the Treatment of Ulcerative Colitis NCT03444311 | AB Biotics, SA | N/A |
| Completed | A Study to Determine the Pharmacokinetics (PK) of Single Intravenous (IV) Dose of Vedolizumab 300 Milligram (m NCT03329209 | Takeda | Phase 1 |
| Completed | To Evaluate the Efficacy and Safety of FE 999315 in Japanese Subjects With Mild to Moderate Active Ulcerative NCT03412682 | Ferring Pharmaceuticals | Phase 3 |
| Completed | Fecal Microbiota Alterations in Steroid Refractory Active Colitis Ulcerosa NCT03460847 | Medical University of Graz | — |
| Terminated | A Study to Assess the Effectiveness and Safety of Treatment With Vedolizumab in Adult Participants With Ulcera NCT03378388 | Takeda | — |
| Completed | Postmarketing Vedolizumab Milk-Only Lactation Study in Lactating Women With Active Ulcerative Colitis or Crohn NCT02559713 | Takeda | Phase 4 |
| Terminated | Detection of Herpesvirus DNA (CMV, EBV, HHV-6 and HSV) in Colonic Tissue: Impact on Ulcerative Colitis Flare-u NCT03172195 | Centre Hospitalier Universitaire de Saint Etienne | N/A |
| Completed | Hyperbaric Oxygen Therapy for Ulcerative Colitis Flares NCT03494764 | Dartmouth-Hitchcock Medical Center | Phase 2 |
| Completed | A Study to Assess Clinical Effectiveness and Safety of Vedolizumab Intravenous in Real World Clinical Practice NCT03535649 | Takeda | — |
| Completed | Anti-tumor Necrosis Factor in Patients With Ulcerative Colitis in Clinical Remission: to Continue or Not? NCT03011268 | Helse Møre og Romsdal HF | N/A |
| Completed | A Study in Patients With Mild or Moderate Ulcerative Colitis Who Take a TNF Inhibitor. The Study Investigates NCT03123120 | Boehringer Ingelheim | Phase 2 |
| Completed | This Study Tests How BI 655130 Works in Patients With Active Ulcerative Colitis. The Study Also Tests How Well NCT03100864 | Boehringer Ingelheim | Phase 2 |
| Completed | MRI in Normal Ileal Pouches, and a Feasibility Study of Dynamic MRI Enema and Defaecating MRI Pouchography NCT02925260 | London North West Healthcare NHS Trust | — |
| Unknown | Two Therapeutic Strategies for the Maintenance of Remission in Patients With Ulcerative Colitis NCT03151525 | Istituto Clinico Humanitas | Phase 4 |
| Completed | Vedolizumab Intravenous (IV) Dose Optimization in Ulcerative Colitis NCT03029143 | Takeda | Phase 4 |
| Completed | Sub-optimal Response to Anti-Tumor Necrosis Factor's in Inflammatory Bowel Disease in Emerging Markets NCT03090139 | Takeda | — |
| Completed | A Study to Observe the Safety and Efficacy of Vedolizumab in Biologically Naive Participants With Ulcerative C NCT02986724 | Takeda | — |
| Completed | Inflammatory Bowel Disease in South Eastern Norway NCT02727959 | Oslo University Hospital | — |
| Unknown | Beneficial and Harmful Effects of Azathioprine and Allopurinol Versus Standard Azathioprine Therapy for Patien NCT03101800 | Hvidovre University Hospital | Phase 3 |
| Completed | GSK2982772 Study in Subjects With Ulcerative Colitis NCT02903966 | GlaxoSmithKline | Phase 2 |
| Terminated | Open-label Extension Study to Assess Safety and Tolerability of LYC-30937-EC in Subjects With Active Ulcerativ NCT02764229 | Lycera Corp. | Phase 2 |
| Withdrawn | Phase 4, Vedolizumab-4002 Post-marketing, Disease-Drug-Drug Interaction Study NCT02760615 | Takeda | Phase 4 |
| Unknown | Mercaptopurine Therapy in Ulcerative Colitis NCT02910245 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | Phase 3 |
| Completed | Safety, Efficacy, and Tolerability Study of PF-06480605 in Subjects With Moderate to Severe Ulcerative Colitis NCT02840721 | Telavant, Inc. | Phase 2 |
| Unknown | Unraveling a Potential Connection Between Bilirubin Metabolism, Gut Microbiota and Inflammatory Bowel Diseases NCT03841045 | Soroka University Medical Center | — |
| Completed | CAsein GLycomacropeptide in Ulcerative Colitis - Anti-Inflammatory and Microbiome Modulating Effects (CAGLUCIM NCT02825914 | University of Aarhus | N/A |
| Terminated | Extended Access Program of Vedolizumab IV in Ulcerative Colitis and Crohn's Disease NCT02743806 | Takeda | Phase 4 |
| Completed | An Efficacy and Safety Study of LYC-30937-EC in Subjects With Active Ulcerative Colitis NCT02762500 | Lycera Corp. | Phase 2 |
| Completed | Effect of a Comprehensive Nutrition Support Product on the Nutritional Status of Adults With Inflammatory Bowe NCT02801240 | National University of Natural Medicine | N/A |
| Unknown | Initial Experience With a Novel Single-Balloon Enteroscopy System in Children With IBD NCT02629211 | Smart Medical Systems Ltd. | N/A |
| Completed | Study of a Monoclonal Antibody KHK4083 in Moderate Ulcerative Colitis NCT02647866 | Kyowa Kirin, Inc. | Phase 2 |
| Unknown | Improving the Health Care in Inflammatory Bowel Disease. NCT02770599 | University Hospital of North Norway | — |
| Completed | Anti-TNF Therapy for Refractory Colitis in Hospitalized Children NCT02799615 | Children's Hospital Medical Center, Cincinnati | — |
| Completed | A Study of Long-term Effects of Vedolizumab Subcutaneous in Adults With Ulcerative Colitis and Crohn's Disease NCT02620046 | Takeda | Phase 3 |
| Completed | Home basEd faecaL calProtectin Measurements Predicting Adalimumab Induction Destiny NCT02634060 | Universitaire Ziekenhuizen KU Leuven | N/A |
| Completed | Patient Centered Algorithms to Optimize the Inpatient Experience and Treatment of Ulcerative Colitis NCT02569333 | Mount Sinai Hospital, Canada | N/A |
| Completed | A Phase 2a, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Trial of IBD98-M NCT02493712 | Holy Stone Healthcare Co., Ltd | Phase 2 |
| Completed | Localized Therapeutics for the Treatment of Gastrointestinal Disorders II NCT02745678 | Stanford University | Phase 1 |
| Completed | Efficacy and Safety of Vedolizumab Subcutaneously (SC) as Maintenance Therapy in Ulcerative Colitis NCT02611830 | Takeda | Phase 3 |
| Completed | An Efficacy and Safety Study of Mongersen (GED-0301) in Subjects With Active Ulcerative Colitis NCT02601300 | Celgene | Phase 2 |
| Completed | OTIS Vedolizumab Pregnancy Exposure Registry NCT02678052 | Takeda | — |
| Completed | Biomarkers in Inflammatory Bowel Diseases NCT02612103 | Line Elberg Godskesen | — |
| Completed | Budesonide 9 mg Capsules in Active UC NCT02550418 | Dr. Falk Pharma GmbH | Phase 2 |
| Completed | Aminosalicylic Acid Withdrawal Study in Long Standing Inactive Ulcerative Colitis NCT02537210 | Chinese University of Hong Kong | N/A |
| Unknown | "Efficacy and Safety of Infliximab-biosimilar (Inflectra) Compared to Infliximab-innovator (Remicade) in Patie NCT02452151 | Onze Lieve Vrouwe Gasthuis | Phase 4 |
| Completed | A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Participants W NCT02407236 | Janssen Research & Development, LLC | Phase 3 |
| Completed | An Open Label Phase 4 Study to Evaluate Efficacy of Early Versus Late Use of Vedolizumab in Ulcerative Colitis NCT02646657 | Geert D'Haens | Phase 4 |
| Completed | An Efficacy and Safety Study of Vedolizumab Intravenous (IV) Compared to Adalimumab Subcutaneous (SC) in Parti NCT02497469 | Takeda | Phase 3 |
| Completed | Remote Ischemic Conditioning in Patients With Ulcerative Colitis NCT02445365 | Odense University Hospital | N/A |
| Completed | Correlation of Infliximab Levels With Outcomes in Ulcerative Colitis NCT02438410 | Mayo Clinic | — |
| Unknown | Confocal Laser Endomicroscopy for Assessment of Mucosal Healing in Ulcerative Colitis NCT02676817 | European Georges Pompidou Hospital | — |
| Completed | Bmgim Music Therapy Method in Reducing Stress in Patients With Inflammatory Bowel Disease NCT03999294 | University of Valencia | N/A |
| Unknown | Golimumab in Steroid-dependent Ulcerative Colitis: Induction and Maintenance of Clinical and Endoscopic Remiss NCT02412085 | Istituto Clinico Humanitas | Phase 4 |
| Completed | Correlation of Soluble Suppression of Tumorigenicity 2 (ST2) With Golimumab (MK-8259) Response in Participants NCT02318667 | Merck Sharp & Dohme LLC | Phase 4 |
| Unknown | Decentralized Dietary UC Pilot Trial NCT02357537 | Transparency Life Sciences | N/A |
| Terminated | Efficacy/Safety Pilot Study to Investigate Iberogast N's Efficacy in Mild to Moderate Colitis Ulcerosa Patient NCT02246686 | Bayer | Phase 2 |
| Completed | The Utility of Second Generation Colon Capsule Endoscopy in Ulcerative Colitis NCT02469103 | Chinese University of Hong Kong | N/A |
| Completed | Patient Attitudes and Preferences for Outcomes of Inflammatory Bowel Disease Therapeutics NCT02316678 | University of Pennsylvania | — |
| Completed | A Study of the Efficacy and Safety of Etrolizumab Treatment in Maintenance of Disease Remission in Ulcerative NCT02165215 | Hoffmann-La Roche | Phase 3 |
| Completed | Study of Clinical Course of Newly Diagnosed Moderate to Severe Ulcerative Colitis in Korea NCT02229344 | Janssen Korea, Ltd., Korea | — |
| Completed | Improving OutcoMes in the Pediatric to Adult Care Transition in Inflammatory Bowel Disease NCT02085083 | Mount Sinai Hospital, Canada | N/A |
| Completed | Telemedicine Crohn's Disease and Ulcerative Colitis (TECCU) NCT02943538 | Instituto de Investigacion Sanitaria La Fe | N/A |
| Completed | Efficacy, Pharmacokinetics, Tolerability, Safety of SB012 Intrarectally Applied in Active Ulcerative Colitis P NCT02129439 | Sterna Biologicals GmbH & Co. KG | Phase 1 / Phase 2 |
| Completed | Induction of Immunity Against Streptococcus Pneumoniae in Adults With Inflammatory Bowel Disease NCT01908283 | Klara M. Pósfay Barbe | Phase 4 |
| Completed | Randomized-controlled Trial of Yoga for Ulcerative Colitis NCT02043600 | Universität Duisburg-Essen | N/A |
| Completed | Single Dose Escalation Trial to Evaluate the Safety, Tolerability Pharmacokinetics and Pharmacodynamics of GSK NCT01984047 | GlaxoSmithKline | Phase 1 |
| Terminated | Safety and Tolerability Study of GSK2586184 in Patients With Moderate to Severely Active Ulcerative Colitis. NCT02000453 | GlaxoSmithKline | Phase 1 |
| Completed | A Study to Evaluate the Accuracy of a Subset of the Length-109 Probe Set Panel (a Genetic Test) in Predicting NCT01988961 | Janssen Research & Development, LLC | Phase 2 |
| Completed | A Study of Safety and Effectiveness of JNJ-54781532 in Patients With Moderately to Severely Active Ulcerative NCT01959282 | Janssen Research & Development, LLC | Phase 2 |
| Terminated | Trichuris Suis Ova Treatment in Left-sided Ulcerative Colitis NCT01953354 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 |
| Completed | A Study to Assess the Safety and Pharmacokinetics of Subcutaneously Administered Golimumab, a Human Anti-TNFα NCT01900574 | Janssen Research & Development, LLC | Phase 1 |
| Completed | A Safety and Effectiveness Study of Golimumab in Japanese Patients With Moderately to Severely Active Ulcerati NCT01863771 | Janssen Pharmaceutical K.K. | Phase 3 |
| Completed | Lipid Mediators in Colonic Biopsies as Biomarkers of Disease Activity of Inflammatory Bowel Diseases NCT01990716 | University Hospital, Toulouse | N/A |
| Withdrawn | A Study to Investigate the Efficacy and Safety of GSK1605786 for Treatment of Patients With Active Ulcerative NCT01658605 | GlaxoSmithKline | Phase 2 |
| Unknown | A RETROspective Data Collection of comPRESSion Anastomosis Using the ColonRing NCT01880918 | novoGI | — |
| Completed | Confocal Laser Endomicroscopy Findings in Patients With Proctosigmoiditis Before and After Initiation of Treat NCT01684514 | Herlev Hospital | N/A |
| Completed | Registry With Information About Colitis Ulcerosa and Familial Adenomatous Polyposis Patients NCT01604564 | Universitaire Ziekenhuizen KU Leuven | — |
| Completed | A Phase 1b Study to Assess the Safety and Anti-inflammatory Effects of Two Different Doses of SRT2104 in Patie NCT01453491 | Sirtris, a GSK Company | Phase 1 |
| Completed | Immune Modulation From Trichuris Trichiura NCT02399683 | University of Aarhus | — |
| Completed | Casein Glycomacropeptide in Active Distal Ulcerative Colitis (Pilot Study) NCT01534312 | University of Aarhus | N/A |
| Completed | The Efficacy and Safety of Cobitolimod (Kappaproct®) in Chronic Active Treatment Refractory Ulcerative Colitis NCT01493960 | InDex Pharmaceuticals | Phase 3 |
| Completed | Pharmacokinetics/Pharmacodynamics Biomarker Study in Active Ulcerative Colitis Patients NCT01284062 | Pfizer | Phase 2 |
| Completed | Induction and Maintenance Study of BMS-936557 Patients With Moderate to Severe Ulcerative Colitis NCT01294410 | Bristol-Myers Squibb | Phase 2 |
| Completed | A Study To Investigate The Safety And Possible Clinical Benefit Of Multistem(r) In Patients With Moderate To S NCT01240915 | Pfizer | Phase 2 |
| Completed | Data Collection of Patients Treated With the ColonRing™ for the Creation of Circular Compression Anastomosis NCT01301417 | novoGI | — |
| Completed | Advanced Metagenomic Analysis of Human Colonic Microbiota in Patients With Chronic GI Disorders NCT01099111 | King Fahad Medical City | — |
| Completed | Mesalamine and Reproductive Health Study NCT01331551 | Harvard School of Public Health (HSPH) | — |
| Completed | (CB-01-02/06) Oral Budesonide-Multi-Matrix System (MMX) 9mg Extended Release Tablets NCT01100112 | Bausch Health Americas, Inc. | Phase 3 |
| Terminated | Conventional Step-Up Versus Infliximab Monotherapy in Patients With Ulcerative Colitis (P05553) NCT00984568 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Effect of GSK1399686 in Patients With Mild to Moderately Active Ulcerative Colitis NCT01036022 | GlaxoSmithKline | Phase 2 |
| Terminated | Study to Evaluate the Pharmacodynamics of SB-656933 in Patients With Ulcerative Colitis NCT00748410 | GlaxoSmithKline | Phase 2 |
| Completed | Study of COLAL-PRED to Treat Moderate to Severe Ulcerative Colitis NCT00676832 | Prometheus Laboratories | Phase 2 |
| Completed | Budesonide Capsules Versus Mesalazine Granules in Active Ulcerative Colitis (UC) NCT00747110 | Dr. Falk Pharma GmbH | Phase 3 |
| Completed | An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcera NCT00488631 | Janssen Research & Development, LLC | Phase 3 |
| Terminated | An Efficacy and Safety Study of Golimumab in Participants With Ulcerative Colitis NCT00488774 | Janssen Research & Development, LLC | Phase 2 / Phase 3 |
| Completed | An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcera NCT00487539 | Janssen Research & Development, LLC | Phase 2 / Phase 3 |
| Completed | An Exploratory Study of Rebamipide in Patients With Active Ulcerative Colitis NCT00463151 | Otsuka Pharmaceutical Co., Ltd. | Phase 2 |
| Completed | Antibiotics for the Treatment of Ulcerative Colitis NCT00355602 | University of Dundee | N/A |
| Terminated | A Dose-finding Study of OPC-6535 in Patients With Active Ulcerative Colitis NCT00317356 | Otsuka Pharmaceutical Co., Ltd. | Phase 2 |
| Completed | Compare Conventional Colonosocpy to Endoscopic AFI, NBI for Dysplasia Detection for Ulcerative Colitis & Chola NCT00587236 | Mayo Clinic | — |
| Completed | Follow-Up Phone Calls After Colorectal Surgery NCT00474097 | University Hospitals Cleveland Medical Center | — |
| Completed | Post-Op Quality of Life After Colorectal Surgery NCT00468455 | University Hospitals Cleveland Medical Center | — |
| Completed | A Study To Investigate The Safety And Efficacy Properties Of PF-00547659 In Patients With Active Ulcerative Co NCT00928681 | Pfizer | Phase 1 |
| Completed | A Study to Investigate the Ileo Neo Rectal Anastomosis Compared to the Ileo Pouch Anal Anastomosis for Patient NCT00922103 | Elisabeth-TweeSteden Ziekenhuis | N/A |
| Completed | Once Daily (OD) Versus Three Times Daily (TID) Dosing With Mesalazine Granules for Prevention of Recurrence of NCT00746447 | Dr. Falk Pharma GmbH | Phase 3 |
| Completed | Anterior Perineal Plane for Ultra Low Anterior Resection of the Rectum NCT00534131 | Queen Mary University of London | N/A |
| Completed | Safety and Tolerability of SPD476 in Maintaining Remission in Patients With Ulcerative Colitis. NCT00151944 | Shire | Phase 3 |
| Completed | Safety and Efficacy of SPD476 (Mesalazine) Given Twice Daily (2.4 g/Day) vs SPD476 Given as a Single Dose (4.8 NCT00503243 | Shire | Phase 3 |
| Completed | Phase II Dose-Ranging Study in Subjects With Mild to Moderate Ulcerative Colitis Treated With SPD476 NCT00545389 | Shire | Phase 2 |
| Available | Provide Pre-approval Single Patient Expanded Access (Compassionate Use) of Etrasimod for Patients. NCT06025227 | Pfizer | — |